Overcoming the shortfalls of ibrutinib with fludarabine in CLL patientss

Inhye Ahn

Inhye Ahn, MD from the National Institutes of Health, Bethesda, MD discusses the leading kinase inhibitor, ibrutinib, at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY. Despite being a leading drug, Dr Ahn mentions some of the shortfalls of using ibrutinib as a single agent including the lack of deep response and the acquisition of drug resistance. Knowing this, a new Phase II study (NCT02514083) was designed using ibrutinib combined with a short course of fludarabine. Dr Ahn reports very encouraging results with an even reduction of the disease in systemic organs.

Share this video